RO5126766 (CH5126766)

Catalog No. A14019

RO5126766 (CH5126766)是对Raf和MEK丝裂原激活的蛋白激酶（MAPK）具有特异性的蛋白激酶抑制剂，具有潜在的抗肿瘤活性。

Product Citations

Yuki Shimizu, .et al. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma, Cancer Lett, 2022, Sep 1;543 PMID: 35724767

Technical details

Catalog Num	A14019
M. Wt	471.5
Formula	C21H18FN5O5S
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	946128-88-7
Synonyms	RO 5126766, RO-5126766, CH5126766, CH-5126766, CH 5126766.
SMILES	CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F

Biological Activity

RO5126766 (CH5126766)是对Raf和MEK丝裂原激活的蛋白激酶（MAPK）具有特异性的蛋白激酶抑制剂，具有潜在的抗肿瘤活性。

Targets

BRAF V600E	BRAF	CRAF	MEK1
8.2 nM	19 nM	56 nM	160 nM

Solubility *

In vitro (25°C)	DMSO	93 mg/mL (197.26 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	5% DMSO+45% PEG 300+ddH2O	19 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	21.21 mL	106.04 mL	212.09 mL
0.5 mM	4.24 mL	21.21 mL	42.42 mL
1 mM	2.12 mL	10.6 mL	21.21 mL
5 mM	0.42 mL	2.12 mL	4.24 mL

*The above data is based on the productmolecular weight 471.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.